Is it more cost-effective to use bevacizumab in the primary treatment setting or at recurrence? An economic analysis

✍ Scribed by K. Fuh; J. Chan; B. Monk; R. Urban; L. Hu; D. Kapp; A. Caughey; X. Yu

• Book ID: 113962956
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 93 KB
• Volume: 120
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2010.12.233